PERINATAL HERPES-VIRUS INFECTION

PERINATAL HERPES-VIRUS INFECTION

Primary Disciplinary Field(s): Neonatology, Obstetrics, Virology, Infectious Disease

1. Core Definition

Perinatal herpes-virus infection, often referred to specifically as neonatal herpes simplex virus (HSV) infection, is a severe, life-threatening complication resulting from the transmission of the Herpes Simplex Virus (typically Type 1 or Type 2) from a mother to her infant during the peripartum period. This period encompasses the late stages of pregnancy, labor, delivery, and the immediate postnatal phase. Unlike common adult manifestations of HSV, which often present as benign cold sores or localized genital lesions, the neonatal infection is characterized by potentially devastating systemic involvement, owing to the immature immune system of the newborn. If untreated, the mortality rate associated with disseminated infection can exceed 80%, and even with aggressive antiviral therapy, significant long-term neurodevelopmental morbidity is common, particularly if the central nervous system (CNS) is involved.

The core mechanism involves the ascent of the virus from the maternal genital tract, which is the most common route of acquisition, or direct contact of the neonate with infected lesions during passage through the birth canal. While the original source content correctly identifies the risk associated with the later stages of pregnancy, it is crucial to understand that the overwhelming majority—approximately 85%—of neonatal HSV infections are acquired during the intrapartum (delivery) period. This heightened risk is primarily related to the presence of active viral shedding in the mother’s genital tract at the time of birth. The resulting infection in the neonate is an acute medical emergency requiring immediate recognition and treatment with high-dose intravenous antiviral medication to mitigate the severe neurological and visceral damage the virus can inflict.

This infection represents a continuum of illness, ranging from localized disease confined to the skin, eyes, and mouth (SEM) to extensive, life-threatening systemic disease involving multiple organs, including the lungs, liver, and brain. The severity is inversely proportional to the speed of diagnosis and initiation of antiviral therapy. A key distinction in the pathology of perinatal HSV is the capacity of the virus to bypass typical immune defenses, leading to rapid viral replication and widespread organ destruction, often culminating in profound coagulopathy (intense blood disorder, as noted in the source material) and destructive herpes simplex encephalitis.

2. Etiology and Modes of Transmission

Perinatal HSV infection is almost exclusively caused by Herpes Simplex Virus Type 1 (HSV-1) or Herpes Simplex Virus Type 2 (HSV-2). Historically, HSV-2, which is the predominant cause of genital herpes, accounted for the vast majority (around 70–85%) of neonatal cases. However, recent epidemiological data suggest that the proportion of neonatal infections caused by HSV-1, often acquired through sexual contact or maternal oral lesions, is increasing, particularly in developed nations. The specific serotype may influence the clinical presentation, though both types are capable of causing the full spectrum of severe, disseminated disease in the newborn. Understanding the maternal infection status—whether it is primary, non-primary first episode, or recurrent—is the paramount factor in determining the risk of transmission.

The route of transmission dictates the timing of acquisition. The most common route, intrapartum transmission, occurs when the neonate is exposed to viral secretions, typically from maternal genital lesions, during delivery. This is the mechanism responsible for up to 85% of cases. The risk is dramatically higher if the mother experiences a primary HSV infection near the time of delivery, as viral shedding is profuse, and protective maternal antibodies have not yet fully developed and crossed the placenta. In contrast, if the maternal infection is a recurrent one, the risk of transmission is relatively low (less than 1–3%) because maternal antibodies provide a degree of protection, and the viral load is typically much lower.

Less common routes include congenital (in utero) transmission and postnatal transmission. Congenital infection (accounting for less than 5% of cases) involves transplacental passage of the virus, usually during a primary maternal viremia, leading to severe fetal damage, including microcephaly, chorioretinitis, and intrauterine growth restriction. Postnatal transmission (5–10% of cases) occurs after birth, usually through contact with non-genital lesions (e.g., cold sores on the mouth or skin lesions) of the mother, father, or hospital staff. This emphasizes the need for rigorous hygiene and caution around newborns when active HSV lesions are present anywhere on caregivers.

3. Epidemiology and Critical Risk Factors

The incidence of neonatal HSV infection varies globally but is generally estimated to be between 1 in 3,000 and 1 in 20,000 live births. Despite its relative rarity compared to other congenital infections, its severity makes it a critical public health concern. The geographical variations are often linked to the prevalence of genital HSV infection within the reproductive-age population. The vast majority of mothers who transmit HSV to their infants are asymptomatic at the time of delivery and unaware they are shedding the virus, making targeted prevention challenging.

The single most important risk factor determining vertical transmission is the timing and type of maternal infection. The highest risk (30–50%) occurs when a woman acquires a primary HSV infection late in the third trimester of pregnancy. During a primary infection, the amount of virus shed is significantly high, and the mother lacks neutralizing antibodies (IgG) necessary to cross the placenta and protect the fetus. If the primary infection occurs early in pregnancy, the risk of congenital infection increases, but the risk of severe neonatal disease acquired at delivery is lessened if the mother seroconverts (develops protective antibodies) before labor.

Other significant risk factors include the use of invasive monitoring procedures during labor, such as fetal scalp electrodes, which can provide a portal of entry for the virus. Furthermore, a prolonged rupture of membranes (over four to six hours) increases the time the neonate is exposed to ascending virus in the birth canal. Delivery method is also crucial; while Cesarean section is often employed to prevent transmission, the source content correctly points out that this does not guarantee safety. A C-section performed before the rupture of membranes or early in labor, when active lesions are present, significantly reduces risk, but if viral ascent has already occurred or if lesions are present outside the cervix, transmission can still happen, leading to maternal distress and confusion regarding preventive measures.

4. Clinical Manifestations in the Neonate

Neonatal HSV infection presents clinically in three major categories, based on the extent of viral dissemination. Symptoms usually appear between birth and four weeks of age, though they may rarely manifest up to six weeks postpartum. These categories are crucial for diagnosis, prognosis, and therapeutic decisions.

• Skin, Eye, and Mouth (SEM) Disease: This is the most localized form, accounting for about 40–50% of cases. Symptoms include characteristic vesicular lesions on the skin, often clustered in areas of trauma or monitoring sites. Ocular involvement manifests as conjunctivitis or keratitis, and oral lesions resemble stomatitis. While the prognosis for SEM disease is generally good if confined, it is vital to note that without treatment, up to 70% of infants with SEM disease will progress to central nervous system (CNS) or disseminated disease, necessitating systemic antiviral therapy regardless of the limited presentation.
• Central Nervous System (CNS) Disease: Accounting for about 30% of cases, CNS disease presents as herpes simplex encephalitis. Symptoms are often nonspecific, including fever, lethargy, poor feeding, irritability, seizures, and hypotonia. HSV encephalitis causes severe focal and global neurological damage due to hemorrhagic necrosis in the brain parenchyma. This manifestation is highly destructive, leading to permanent neurological sequelae such as developmental delay, microcephaly, and spasticity in the majority of survivors.
• Disseminated Disease (DIS): The most severe form (20–30% of cases), DIS involves multiple major organs, mimicking sepsis. The most commonly affected organs are the liver, lungs, and adrenal glands. Infants present with signs of systemic illness, including jaundice, coagulopathy (reflecting severe liver failure and the intense blood disorder mentioned in the source material), respiratory distress (pneumonitis), shock, and disseminated intravascular coagulation (DIC). Cutaneous vesicles may be absent in up to one-third of infants with disseminated disease, complicating early clinical recognition and often leading to delays in diagnosis that contribute heavily to the high mortality rate.

5. Diagnosis and Screening Protocols

Early and accurate diagnosis is essential, as clinical suspicion alone often mandates the initiation of presumptive treatment. Because the clinical presentation of neonatal HSV, especially the disseminated form, can mimic bacterial sepsis, diagnostic evaluation must be thorough and rapid.

Diagnostic confirmation relies primarily on the detection of the virus via Polymerase Chain Reaction (PCR). PCR testing should be performed on multiple sites: cerebrospinal fluid (CSF) to diagnose CNS involvement, blood (to detect viremia associated with disseminated disease), and surface swabs taken from the nasopharynx, eyes, rectum, and any suspected skin lesions. The CSF PCR is the gold standard for diagnosing HSV encephalitis, although it may initially be negative and should be repeated if clinical suspicion remains high.

Additional diagnostic tests include viral culture (though less sensitive and slower than PCR), evaluation of liver function tests (often elevated in disseminated disease), and complete blood count. Brain imaging, specifically magnetic resonance imaging (MRI), is crucial in CNS disease to identify hemorrhagic and necrotic lesions characteristic of HSV encephalitis. For maternal screening, serology (antibody testing) is not useful for acute diagnosis but can help determine if a mother has a primary or recurrent infection, which assists in assessing risk prenatally. However, routine screening of all pregnant women for asymptomatic HSV is generally not recommended due to low positive predictive values and high costs.

6. Management and Treatment Strategies

The cornerstone of management for confirmed or suspected neonatal HSV infection is immediate, high-dose intravenous administration of the antiviral agent Acyclovir. Treatment must be initiated empirically in any neonate presenting with symptoms suggestive of sepsis, disseminated infection, or unexplained CNS illness, pending diagnostic test results, especially if there is a known history of maternal genital herpes.

The standard treatment protocol involves administering Acyclovir intravenously for a duration dependent on the disease classification. For SEM disease, 14 days of IV Acyclovir is typically sufficient. However, for CNS disease or disseminated disease, the recommended duration is significantly longer, typically 21 days, to ensure adequate penetration into the brain and eradication of the systemic infection. Following the initial intravenous course for CNS or disseminated disease, infants are often placed on long-term suppressive oral Acyclovir for six months. This suppressive therapy has been shown to improve neurodevelopmental outcomes by preventing late recurrences of the virus, which can cause progressive neurological damage even after the initial systemic infection has cleared.

Supportive care is also critically important, particularly in disseminated cases. This includes intensive care monitoring, respiratory support, management of shock, correction of coagulopathies (which can involve blood product transfusions), and seizure management. Due to the high risk of long-term neurodevelopmental impairment, multidisciplinary follow-up, including neurology, ophthalmology, and developmental pediatric services, is mandatory for all infants who have survived CNS or disseminated disease.

7. Prevention and Prognosis

Prevention focuses on mitigating the risk of transmission, primarily during labor and delivery. The key preventive measure involves identifying women at high risk—those experiencing a first episode (primary or non-primary) genital HSV infection near term. For these women, delivery by Cesarean section is strongly recommended to minimize the infant’s exposure to active viral shedding. For women with recurrent genital herpes, the risk is much lower, and a vaginal delivery is usually permissible, provided there are no active lesions or prodromal symptoms (like vulvar pain or tingling) at the onset of labor.

Antiviral prophylaxis plays an increasingly important role. Pregnant women with a history of recurrent genital herpes are often prescribed oral Acyclovir or Valacyclovir starting at 36 weeks gestation until delivery. This prophylactic regimen significantly reduces the frequency of viral recurrences and asymptomatic shedding at term, thereby lowering the need for C-sections and reducing the risk of neonatal transmission. Furthermore, education regarding postnatal transmission routes is crucial; mothers and caregivers with oral lesions (cold sores) must practice meticulous hand hygiene and avoid kissing the neonate until the lesion is healed.

The prognosis for perinatal HSV infection is directly related to the disease classification and the speed of treatment. Infants with isolated SEM disease who receive prompt treatment have an excellent prognosis for survival, although they still carry a risk of long-term ocular or neurodevelopmental deficits if progression occurs. In contrast, mortality rates for disseminated or CNS disease, even with Acyclovir therapy, remain tragically high, ranging from 15% to 30%. Among survivors of CNS disease, up to 90% will experience severe neurological impairment, highlighting why perinatal HSV remains one of the most feared infectious complications in neonatology.

Further Reading

• Centers for Disease Control and Prevention (CDC) – Genital Herpes
• Wikipedia – Herpes Simplex Virus
• NCBI Bookshelf – Neonatal Herpes Simplex Virus Infection